A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC).
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- 09 Aug 2017 Status changed from active, no longer recruiting to completed.
- 15 Oct 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
- 09 Dec 2014 Planned primary completion date changed from 1 Dec 2013 to 1 Jun 2015 as reported by ClinicalTrials.gov.